Table 3.
Association between genetic alterations and ypT0/isypN0 in different breast cancer subtypes
| Characteristics | N (%)a | HR−HER2− | χ2 | P | HR−HER2+ | χ2 | P | HR+HER2+ | χ2 | P | HR+HER2− | χ2 | P | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Yes | No | Yes | No | Yes | No | Yes | ||||||||||
| TP53 mutation | |||||||||||||||||
| No | 98 (40.0) | 2 (66.7) | 1 (33.3) | .370 | .501 | 3 (60.0) | 2 (40.0) | <.001 | 1.000 | 8 (80.0) | 2 (20.0) | .017 | .897 | 79 (98.8) | 1 (1.2) | 2.472 | .178 |
| Yes | 147 (60.0) | 22 (81.5) | 5 (18.5) | 12 (60.0) | 8 (40.0) | 27 (81.8) | 6 (18.2) | 63 (94.0) | 4 (6.0) | ||||||||
| PIK3CA mutation | |||||||||||||||||
| No | 136 (55.5) | 16 (80.0) | 4 (20.0) | <.001 | 1.000 | 7 (43.8) | 9 (56.2) | 4.890 | .040 | 22 (81.5) | 5 (18.5) | <.001 | 1.000 | 70 (95.9) | 3 (4.1) | .221 | .681 |
| Yes | 109 (44.5) | 8 (80.0) | 2 (20.0) | 8 (88.9) | 1 (11.1) | 13 (81.2) | 3 (18.8) | 72 (97.3) | 2 (2.7) | ||||||||
| ERBB2 amplification | |||||||||||||||||
| No | 180 (73.5) | 22 (78.6) | 6 (21.4) | .536 | 1.000 | 2 (66.7) | 1 (33.3) | .063 | 1.000 | 9 (100.0) | 0 (0) | 2.602 | .171 | 136 (97.1) | 4 (2.9) | 2.650 | .219 |
| Yes | 65 (26.5) | 2 (100.0) | 0 (0) | 13 (59.1) | 9 (40.9) | 26 (76.5) | 8 (23.5) | 6 (85.7) | 1 (14.3) | ||||||||
| MYC amplification | |||||||||||||||||
| No | 150 (61.2) | 12 (92.3) | 1 (7.7) | 2.172 | .196 | 8 (44.4) | 10 (55.6) | 6.481 | .020 | 25 (86.2) | 4 (13.8) | 1.362 | .404 | 89 (98.9) | 1 (1.1) | 3.705 | .074 |
| Yes | 95 (38.8) | 12 (70.6) | 5 (29.4) | 7 (100.0) | 0 (0) | 10 (71.4) | 4 (28.6) | 53 (53.0) | 4 (7.0) | ||||||||
| CCND1 amplification | |||||||||||||||||
| No | 208 (84.9) | 23 (82.1) | 5 (17.9) | 1.205 | .366 | 13 (56.5) | 10 (43.5) | 1.449 | .500 | 28 (77.8) | 8 (22.2) | 1.911 | .315 | 116 (95.9) | 5 (4.1) | 1.112 | .586 |
| Yes | 37 (15.1) | 1 (50.0) | 1 (50.0) | 2 (100.0) | 0 (0) | 7 (100.0) | 0 (0) | 26 (100.0) | 0 (0) | ||||||||
| Retinoblastoma pathway alteration | |||||||||||||||||
| No | 183 (74.7) | 21 (84.0) | 4 (16.0) | 1.500 | .254 | 12 (60.0) | 8 (40.0) | <.001 | 1.000 | 23 (74.2) | 8 (25.8) | 3.805 | .082 | 104 (97.2) | 3 (2.8) | .427 | .613 |
| Yes | 62 (23.7) | 3 (60.0) | 2 (40.0) | 3 (60.0) | 2 (40.0) | 12 (100.0) | 0 (0) | 38 (95.0) | 2 (5.0) | ||||||||
| Mitogen‐activated protein kinase pathway alteration | |||||||||||||||||
| No | 165 (67.3) | 12 (75.0) | 4 (25.0) | .536 | .657 | 15 (62.5) | 9 (37.5) | 1.563 | .400 | 28 (77.8) | 8 (22.2) | 1.911 | .315 | 86 (96.6) | 3 (3.4) | .001 | 1.000 |
| Yes | 80 (32.7) | 12 (85.7) | 2 (14.3) | 0 (0) | 1 (100.0) | 7 (100.0) | 0 (0) | 56 (96.6) | 2 (3.4) | ||||||||
| Phosphatidylinositol‐3‐kinase pathway alteration | |||||||||||||||||
| No | 106 (43.3) | 13 (81.2) | 3 (18.8) | .033 | 1.000 | 7 (53.8) | 6 (46.2) | .427 | .688 | 19 (79.2) | 5 (20.8) | .178 | 1.000 | 51 (96.2) | 2 (3.8) | .035 | 1.000 |
| Yes | 139 (56.7) | 11 (78.6) | 3 (21.4) | 8 (66.7) | 4 (33.3) | 16 (84.2) | 3 (15.8) | 91 (96.8) | 3 (2.2) | ||||||||
a
Two cases with no records of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status were not included in this table.